Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cavosonstat MAD Study in Healthy Subjects
NCT02934139Phase 1Completed
- Sponsor
- Nivalis Therapeutics
- Start
- Oct 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cavosonstat in cystic fibrosis (CF) (5 arms), sponsored by Nivalis Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 14 days. Started Oct 2016; status: completed.
02
Drugs
cavosonstat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02934139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934139.